Surrozen, Inc./DE Weighted Average Number of Shares Outstanding, Basic and Diluted
Surrozen, Inc./DE (SRZN) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 34.86 thousand shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-11
- Surrozen, Inc./DE weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 34.86K shares, a 92.04% increase year-over-year.
- Surrozen, Inc./DE weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 34.88M shares, a 92.67% increase year-over-year.
- Surrozen, Inc./DE weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 27.40M shares, a 48.06% increase year-over-year.
- Surrozen, Inc./DE weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 18.15K shares.
- Surrozen, Inc./DE weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 24.69M shares, a 54.58% increase from fiscal 2020.
- Surrozen, Inc./DE weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 15.97M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 1 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | 34.86K shares 10-Q · filed 2022-05-11 | 17.46M shares derived: average of 2 quarters · filed 2022-05-11 | 20.77M shares derived: average of 3 quarters · filed 2022-05-11 | ||
| 2021-12-31 | 34.88M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 31.14M shares derived: average of 2 quarters · filed 2022-03-28 | 24.69M shares 10-K · filed 2022-03-28 | ||
| 2021-09-30 | 27.40M shares 10-Q · filed 2021-11-15 | 21.29M shares 10-Q · filed 2021-11-15 | |||
| 2021-03-31 | 18.15K shares 10-Q · filed 2022-05-11 | 9.06M shares derived: average of 2 quarters · filed 2022-05-11 | 12.21M shares derived: average of 3 quarters · filed 2022-05-11 | ||
| 2020-12-31 | 18.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 18.31M shares derived: average of 2 quarters · filed 2022-03-28 | 15.97M shares 10-K · filed 2022-03-28 | ||
| 2020-09-30 | 2.30M shares 10-Q/A · filed 2021-01-05 | 18.51M shares 10-Q · filed 2021-11-15 | 15.26M shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |